Asia Pharmaceuticals and Healthcare Report Q4 2016
|出版日期||內容資訊||英文 39 Pages
|亞洲的醫藥品、醫療產業 (季度更新報告) Asia Pharmaceuticals and Healthcare Report Q4 2016|
|出版日期: 2016年10月26日||內容資訊: 英文 39 Pages||
本報告提供亞洲各國的製藥產業及醫療產業相關分析，地區整體產業規模的實際成果值、預測值 (過去5年、今後10年份) 估計，產業的課題 (風險) 和未來性的商機 (利潤) 相關評估，域內各地區詳細趨勢，主要企業簡介等資訊彙整，為您概述為以下內容
BMI View: Private healthcare providers will become a central part of Asia's medical landscape. Galvanised by the growing demand for medical services across the region and the shortfall in supply from public facilities, these firms are expected to expand their presence steadily over the coming years. These companies can be categorised into two broad groups: regional healthcare providers such as Raffles Medical Group and more domestic-focused firms such as Siloam International Hospital. This trend will shape the flow of patients, with commercial implications for pharmaceutical sales. It can also serve as a source of competition should domestic drugmakers diversify into medical provision.
In BMI's Pharmaceutical Q416 Risk/Reward Index (RRI), the Asia Pacific region scores 52.4 out of 100, comparing relatively well with Central and Eastern Europe (52.4), the Americas (50.5) and the Middle East and Africa (40.4) region but below Western Europe (70.6). The indicators used to assess the attractiveness of a pharmaceutical market are now visible, improving the transparency of the index system and enabling the identification of regional or group outperformers across single indicators. A market's RRI score is made up of a sum of the Rewards score (Industry Rewards + Country Rewards) and the Risks score (Industry Risks + Country Risks).